Which digital therapeutics are actually reimbursed — and where?

What "reimbursed" means here

Reimbursement rules vary enormously by country, and vendor claims are often optimistic. This project draws a hard line: a product is only listed as reimbursed if it appears in an official statutory registry (e.g. Germany's DiGA directory), a national tariff/fee schedule (e.g. US Medicare G-codes, Japan's Chuikyo listing), or a documented insurer/employer agreement.

Products that are merely recommended by a clinical body (like the UK's ORCHA library or Denmark's Sundhedsapps council) without an actual payment mechanism behind them are shown separately, clearly labelled, for context rather than counted as reimbursed.

• 1Primary sources first. Statutory registries, tariff documents, and payer/insurer publications are checked before any vendor page.
• 2Country-by-country research. Each market's reimbursement pathway (DiGA, LPPR, MiGeL, NHI, Medicare G-codes, etc.) is researched on its own terms rather than forced into one template.
• 3Explicit uncertainty. Where a claim (like an ongoing clinical study) hasn't been independently registry-checked yet, that's marked rather than assumed.